Our group strongly opposes the extension of the problematic 340B drug pricing program.
In a recent statement, the advocacy organisation Action, an affiliate of the Association of Mature American Citizens, has strongly urged the rejection of H.R. 4581, the 340B PATIENTS Act of 2025. The bill, which aims to expand the 340B Drug Pricing Program, has raised significant concerns among the organisation's leadership.
The 340B Drug Pricing Program, established to help vulnerable populations access affordable medications, has, over many years, drifted from its original mission. The program, as it stands, continues to be exploited by entities that pocket discounted drug pricing while seniors are charged full retail prices. The bill, unfortunately, does not curb the high out-of-pocket medication costs for seniors, a group that bears the brunt of the system's issues.
Andrew J. Mangione Jr., Senior Vice President of Action, expressed his concerns in a letter signed by him. He stated that expanding the 340B program without transparency and measurable outcomes is fiscally irresponsible, especially at a time when inflation and government spending are top concerns for older Americans.
The legislation lacks safeguards, and the growing number of contract pharmacies under 340B has not translated into better access for rural or underserved seniors. In fact, many of these pharmacies are concentrated in affluent areas, far from the seniors most in need of affordable prescriptions, creating a geographic imbalance.
The bill is likely to enable the continuation of pricing practices that offer little to no relief to the patients the program was intended to help, particularly low-income seniors living on fixed incomes. Instead of ensuring affordable medications for the truly needy, the program has evolved into a profit center for powerful hospital networks and corporate pharmacy middlemen.
Action, with over 2 million members nationwide, stands firm in its opposition to the 340B PATIENTS Act of 2025. The organisation believes that the bill risks deepening a system already plagued by unchecked profiteering, and it does not deliver the kind of accountability and oversight taxpayers deserve.
In conclusion, Action urges policymakers to reconsider the 340B PATIENTS Act of 2025 and work towards a solution that truly addresses the needs of our nation's seniors, ensuring they have access to affordable medications without the burden of exorbitant costs.
Read also:
- Inadequate supply of accessible housing overlooks London's disabled community
- Strange discovery in EU: Rabbits found with unusual appendages resembling tentacles on their heads
- Duration of a Travelling Blood Clot: Time Scale Explained
- Fainting versus Seizures: Overlaps, Distinctions, and Proper Responses
